Background A Task Force was convened by the EFNS / MDS ‐ ES Scientist Panel on P
arkinson's disease ( PD ) and other movement disorders to systemically review relevant …

After more than 40 years of clinical use, levodopa (LD) remains the gold standard of
symptomatic efficacy in the drug treatment of Parkinson’s disease (PD). Compared with other …

Non-motor symptoms (NMS) of Parkinson's disease remain the most under-appreciated and
under-researched when taken as a whole. Data is emerging that it is the “totaL” burden of …

Background: PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria,
published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for …

Background Ergot-derived dopamine receptor agonists, often used in the treatment of
Parkinson's disease, have been associated with an increased risk of valvular heart disease. …

LETTERS TO NATURE Page 1 LETTERS TO NATURE not included in our analysis; the
morphological characters most useful for discriminating S. guntheri were length of longest neck …

We examined the effect of reactive oxygen species (ROS) on MicroRNAs (miRNAs)
expression in endothelial cells in vitro, and in mouse skeletal muscle following acute hindlimb …

If vision in one eye is blurred or occluded during a critical period in postnatal development,
neurons in the visual cortex lose their responses to stimulation through that eye within a few …

We used PET scans with the tracers [ 18 F]fluorodeoxyglucose (FDG) and [ 11 C]raclopride (RACLO)
to study glucose metabolism and dopamine D 2 receptor binding in the caudate …

To date, the ketamine/PCP model of psychosis has been proposed to be one of the best
pharmacological models to mimic schizophrenic psychosis in healthy volunteers, since …